Oncotarget is one of the most reputed science journals in the world that is published by the highly renowned Impact Journals. Oncotarget was established in the year 2010 with the aim to advance and mobilize the information and research on oncology among the peers and the aspirants in the field of oncology. It is a peer-reviewed publication, and thus, it holds authority in the area of oncology and is referenced by oncologists worldwide. It has two of the most famous scientists and oncologists as its editors-in-chief, which includes Andrei V. Gudkov and Mikhail Blagosklonny.
One of the primary reasons why Oncotarget is getting so popular among the people is because of the multiple peer review, constructive and punctual insight and broad range of accurate information available in it. The journal is also the sponsors for the Gordon Research Conference. Other than Oncology, scientists and research assistants can also submit papers from different fields, such as Pharmacology, Neuroscience, Cardiology, Cell Biology, Endocrinology, and more. The editorial board of Oncotarget consists of some of the most sought after names in the field of oncology and hails from some of the top universities and research institutions in the world. Learn more about Oncotarget at Bioxbio.com.
Oncotarget aims to improve and accelerate the advancement in the development of effective cancer therapies. Even though there are many journals in the field of antibody technologies and cancer treatments, Oncotarget aims to stand out in the competition because of its transparent and stringent reviewing process. It is indexed online at multiple sources, including PubMed, Biological Abstracts, Science Citation Index Expanded, Biosis Previews, Embase, Scopus, and more. It is readily available to all the registered research assistant, scientists, and physicians.
Oncotarget aims to mobilize the research, statistics, share the evidence of various cancer therapies, and more across the globe. It helps in ensuring that the development and progress in the field of oncology continue uninterrupted and groundbreaking results are achieved sooner than expected.